SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …

Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD).
But the mechanism for such protection is not clear. Here, we report that in damaged proximal …

Background Despite available interventions, people with type 2 diabetes (T2D) remain at
risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …

Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …

Long-term exposure to a diabetic environment leads to changes in bone metabolism and
impaired bone micro-architecture through a variety of mechanisms on molecular and …